{
  "title": "Paper_1149",
  "abstract": "Mol Cancer Ther Mol Cancer Ther 319 nihpa Molecular cancer therapeutics 1535-7163 1538-8514 pmc-is-collection-domain yes pmc-collection-title NIHPA Author Manuscripts PMC12475887 PMC12475887.1 12475887 12475887 NIHMS2106254 40908151 10.1158/1535-7163.MCT-24-0873 NIHMS2106254 NIHPA2106254 1 Article Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma Xu Yuan 1 Medina Cristian G. 1 Surman Deborah R. 2 Dobrolecki Lacey E. 3 Vilchis Monica 1 Ramineni Maheshwari 4 Hilsenbeck Susan G. 3 Li Yanming 5 6 Li Naren 1 Wu Siqi 1 Aggison Jaylon C. 1 Chen Xi 7 Zhu Yi 7 Shen Ying H. 5 6 Ripley R. Taylor 1 1. 2. 3. 4. 5. 6. 7. Authorsâ€™ contributions Y. X. and C. M.: Conceptualization, experiments, data curation, formal analysis, investigation, methodology, writing original draft, writing review, and editing. L.D., M. V., D. S., M.R., S.G.H., X.C., SQ W., YM L.: Data curation, formal analysis, methodology, writing review, and editing. Y. Z., H.Y. S, M. TL.: Resources, supervision, validation, investigation. RT.R.: Conceptualization, resources, funding acquisition, formal analysis, supervision, methodology, project administration, writing review, and editing Corresponding Author: R.Taylor.Ripley@bcm.edu The authors declare no competing financial interests 05 9 2025 497680 OF1 OF13 22 09 2025 27 09 2025 28 09 2025 28 09 2025 Diffuse mesothelioma (DM) is a rare but highly aggressive and treatment resistant neoplasm with low survival rates. Effective therapeutic strategies are limited, and resistance to treatment is a major obstacle. Myeloid Cell Leukemia (MCL)-1 and B-cell leukemia (BCL)-xL are anti-apoptotic B-cell lymphoma 2 (Bcl-2) family proteins that block cell-intrinsic apoptosis through interactions on the mitochondrial outer membrane which contribute to therapeutic resistance. We investigated whether B-cell homology domain (BH)-3 profiles were consistent between intra-patient fresh tumor sample, patient-derived cells (PDC), and patient-derived xenografts (PDX) by BH3 profiling; we observed striking consistency which enabled cross model comparisons. Next, we co-targeted BCL-xl and MCL-1 and noted that the combination synergistically reduced cell viability and increased apoptosis. Mechanistically, BCL-xL inhibition affected the cells through both the canonical and the emerging non-canonical apoptotic pathways. BCL-xL induced mitochondrial depolarization which resulted in MCL-1 cellular dependency rendering cells highly sensitive to MCL-1 inhibition. Next, we co-targeted BCL-xL and MCL-1 in vivo which induced synthetic lethality in PDX models within hours, implying that this approach is not a safe strategy for clinical development. However, targeting MCL-1, which exerts its anti-apoptotic activity without non-apoptotic on-target effects, decreased the mitochondrial threshold for apoptosis and enhanced chemosensitivity without toxicity in PDX models. Our findings suggest that targeting the mitochondria via MCL-1 enhances the efficacy of chemotherapy but co-targeting two proteins in the Bcl-2 pathways results in synergistic lethality. These results will help define a safe clinical strategy to utilize Bcl-2 targeted therapy to undermine therapeutic resistance in patients with DM. pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access no pmc-prop-olf yes pmc-prop-manuscript yes pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement yes pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes ",
  "metadata": {
    "Title of this paper": "Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma",
    "Journal it was published in:": "Molecular cancer therapeutics",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12475887/"
  }
}